Oragenics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report covers the 2015 Annual Meeting of Shareholders held on July 16, 2015. The filing reports on the outcomes of shareholder votes regarding director elections, executive compensation, and auditor ratification.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes and Voting Results
Shareholders voted on three proposals at the annual meeting:
- Proposal I (Election of Directors): All five nominees were re-elected. Broker non-votes totaled 5,805,776 for each director.
- Dr. Frederick Telling: 24,374,527 For; 2,074,276 Withheld.
- Ms. Christine Koski: 25,822,258 For; 626,545 Withheld.
- Mr. Robert Koski: 25,824,618 For; 624,185 Withheld.
- Mr. Charles Pope: 23,985,409 For; 2,463,394 Withheld.
- Dr. Alan Dunton: 24,063,150 For; 2,385,653 Withheld.
- Proposal II (Executive Compensation Advisory Vote): Approved with 26,117,066 For, 264,025 Against, and 67,712 Abstain.
- Proposal III (Auditor Ratification): Mayer Hoffman McCann P.C. was ratified with 32,215,650 For, 34,824 Against, and 4,105 Abstain.
Outlook, Risks, and Management Commentary
On July 17, 2015, the Company issued a press release confirming the re-election of the Board of Directors. The filing does not contain specific management commentary on future outlook, risks, contingencies, or unusual items beyond the governance updates.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Review the attached press release (Exhibit 99.1) for any additional details on the Board's strategic direction.
- Confirm the independence status of the newly re-elected directors.
- Check subsequent filings for the Company's financial results, as this 8-K contains no financial data.